title: Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes.
abstract: Leptin has metabolic effects on peripheral tissues including muscle, liver, and pancreas, and it has been successfully used to treat lipodystrophic diabetes, a leptin-deficient state. To study whether leptin therapy can be used for treatment of more common cases of type 2 diabetes, we used a mouse model of type 2 diabetes (MKR mice) that show normal leptin levels and are diabetic due to a primary defect in both IGF-I and insulin receptors signaling in skeletal muscle. Here we show that leptin administration to the MKR mice resulted in improvement of diabetes, an effect that was independent of the reduced food intake. The main effect of leptin therapy was enhanced hepatic insulin responsiveness possibly through decreasing gluconeogenesis. In addition, the reduction of lipid stores in liver and muscle induced by enhancing fatty acid oxidation and inhibiting lipogenesis led to an improvement of the lipotoxic condition. Our data suggest that leptin could be a potent antidiabetic drug in cases of type 2 diabetes that are not leptin resistant.
authors.affiliation: Diabetes Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Room 8D12, Building 10, MSC 1758, National Institutes of Health, Bethesda, Maryland 20892-1758, USA.
authors.forename: Yuka
authors.initials: Y
authors.lastname: Toyoshima
authors.forename: Oksana
authors.initials: O
authors.lastname: Gavrilova
authors.forename: Shoshana
authors.initials: S
authors.lastname: Yakar
authors.forename: William
authors.initials: W
authors.lastname: Jou
authors.forename: Stephanie
authors.initials: S
authors.lastname: Pack
authors.forename: Zeenat
authors.initials: Z
authors.lastname: Asghar
authors.forename: Michael B
authors.initials: MB
authors.lastname: Wheeler
authors.forename: Derek
authors.initials: D
authors.lastname: LeRoith
mesh_terms: D055372:AMP-Activated Protein Kinases; D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D004195:Disease Models, Animal; D004435:Eating; D004734:Energy Metabolism / Q000187:drug effects; D006943:Hyperglycemia / Q000188:drug therapy* / Q000378:metabolism; D006946:Hyperinsulinism / Q000188:drug therapy / Q000378:metabolism; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D000078790:Insulin Secretion; D020738:Leptin / Q000494:pharmacology*; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D008817:Mice, Mutant Strains; D009097:Multienzyme Complexes / Q000378:metabolism; D018482:Muscle, Skeletal / Q000201:enzymology; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D014280:Triglycerides / Q000378:metabolism
chemical_list: D001786:Blood Glucose; D007328:Insulin; D020738:Leptin; D009097:Multienzyme Complexes; D014280:Triglycerides; D017346:Protein Serine-Threonine Kinases; D055372:AMP-Activated Protein Kinases